I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, has announced the opening of its Hong Kong office. The newest addition expands I-Mab’s existing footprint in Shanghai, Beijing and Rockville, MD. The Hong Kong office, located in Central, will serve as a regional hub for capital markets and investor relations activities for I-Mab. 
 
“We are delighted to announce this addition to I-Mab’s global footprint. By establishing a presence in Hong Kong, we look forward to engaging with a rich network of investors, capital market practitioners and potential partners about our mission to bring transformational and innovative medicines to patients across the globe,” said Dr. Jingwu Zang, founder, honorary chairman and director of I-Mab.
 
I-Mab is the first China-based global biotech company to successfully complete a US IPO since 2017, listing on the NASDAQ Global Market in January 2020. I-Mab has established pipeline of more than ten clinical and pre-clinical stage assets since its establishment in 2016. I-Mab has advanced a number of its globally competitive innovative assets in clinical trials in the US and is running multiple phase 2 and 3 clinical trials in China. By focusing exclusively on discovery, development and soon commercialization of­ innovative biologics, including monoclonal antibodies (mAbs), fusion proteins and bispecific antibodies that are novel or highly differentiated for cancer and autoimmune diseases, I-Mab aims to tap into the rapidly expanding biologics market. That market is estimated to be worth approximately USD469.9 billion by 2025¹.
 
“The opening of our Hong Kong office marks an exciting new chapter in I-Mab’s journey. Since our establishment in 2016, I-Mab has rapidly grown to become one of the world’s most innovative biotech companies. This latest strategic move to establish a presence in Hong Kong will allow us to maximize our fund-raising potential and capital market connectivity,” said Jielun Zhu, CFO and director of I-Mab.